Cargando…
Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer
SIMPLE SUMMARY: The method of treatment evaluation in patients with chronic breast cancer may affect clinical decision making and treatment protocols. In this study, we compared the two imaging modalities for the evaluation of treatment responses in 65 patients with spread breast cancer. We included...
Autores principales: | Naghavi-Behzad, Mohammad, Oltmann, Hjalte Rasmus, Alamdari, Tural Asgharzadeh, Bülow, Jakob Lykke, Ljungstrøm, Lasse, Braad, Poul-Erik, Asmussen, Jon Thor, Vogsen, Marianne, Kodahl, Annette Raskov, Gerke, Oke, Hildebrandt, Malene Grubbe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392540/ https://www.ncbi.nlm.nih.gov/pubmed/34439232 http://dx.doi.org/10.3390/cancers13164080 |
Ejemplares similares
-
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
por: Vogsen, Marianne, et al.
Publicado: (2021) -
Cost-effectiveness of 2-[(18)F]FDG-PET/CT versus CE-CT for response monitoring in patients with metastatic breast cancer: a register-based comparative study
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2023) -
Prognostic Value of Dual-Time-Point (18)F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2020) -
2-[(18)F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer
por: Vogsen, Marianne, et al.
Publicado: (2023) -
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020)